Matt Abernethy insider trades

Open-market stock purchases and sales by Matt Abernethy, Chief Financial Officer at Neurocrine Biosciences Inc, from SEC Form 4 filings since Dec 1, 2017.

Recent trades

DateStockTradeValue
Sep 14, 2026NBIX Neurocrine Biosciences IncSold$363K
Sep 11, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Sep 11, 2026NBIX Neurocrine Biosciences IncSold (not open market)$423K
Jun 12, 2026FATE Fate Therapeutics IncBought (not open market)—
Mar 4, 2026NBIX Neurocrine Biosciences IncSold (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$150K
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$172K
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$668K
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 12, 2026NBIX Neurocrine Biosciences IncSold (not open market)$142K
Feb 12, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Jan 31, 2026NBIX Neurocrine Biosciences IncSold (not open market)$186K
Jan 31, 2026NBIX Neurocrine Biosciences IncBought (not open market)—

Companies traded

  • NBIX Neurocrine Biosciences Inc: 35 sales, last Sep 14, 2026
  • FATE Fate Therapeutics Inc: other filings, last Jun 12, 2026

Get free alerts when Matt Abernethy files a new trade →